• Home
  • Search
  • Long-Term Experience with Large Granular Lymphocytic Leukemia Evolving after Solid Organ and Hematopoietic Stem Cell Transplantation
  • https://doi.org/10.1182/blood-2019-130167Copy DOI Icon

Long-Term Experience with Large Granular Lymphocytic Leukemia Evolving after Solid Organ and Hematopoietic Stem Cell Transplantation

  • Nov 13, 2019
  • Blood
  • Hassan Awada +14 more
Show More
  • Abstract
  • Literature Map
  • Similar Papers
Abstract

Long-Term Experience with Large Granular Lymphocytic Leukemia Evolving after Solid Organ and Hematopoietic Stem Cell Transplantation

Similar Papers
  • Abstract
  • Citations1

Efficacy and Safety of Front-Line Venetoclax and Rituximab (VenR) for the Treatment of Young Patients with Chronic Lymphocytic Leukemia and an Unfavorable Biologic Profile. Preliminary Results of the Gimema Study ‘Veritas‘

  • Nov 05, 2020
  • Blood
  • Francesca Romana Mauro +44
  • Abstract
  • Citations15

Efficacy of Tisagenlecleucel in Adult Patients (Pts) with High-Risk Relapsed/Refractory Follicular Lymphoma (r/r FL): Subgroup Analysis of the Phase II Elara Study

  • Nov 05, 2021
  • Blood
  • Catherine Thiéblemont +33
  • Abstract
  • Citations6

A Phase 1b/2 Study of the CD123-Targeting Antibody-Drug Conjugate IMGN632 As Monotherapy or in Combination with Venetoclax and Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia

  • Nov 05, 2021
  • Blood
  • Naval Daver +27
  • Abstract
  • Citations9

Stem Cell Collection with Daratumumab (DARA)-Based Regimens in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) in the Griffin and Master Studies

  • Nov 05, 2021
  • Blood
  • Saurabh Chhabra +29
  • Abstract
  • Citations9

Maintenance Therapy with the Oral Proteasome Inhibitor (PI) Ixazomib Significantly Prolongs Progression-Free Survival (PFS) Following Autologous Stem Cell Transplantation (ASCT) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Phase 3 Tourmaline-MM3 Trial

  • Nov 29, 2018
  • Blood
  • Meletios A Dimopoulos +23
  • Abstract

Genomic Landscape and Molecular Risk in Patients with Advanced Myelofibrosis Treated within the Multicenter Phase Ib/II MPNSG0212 (POMINC) Trial

  • Nov 05, 2021
  • Blood
  • Ekaterina Panina +23
  • Abstract
  • Citations1

Brentuximab Vedotin with Chemotherapy for Stage 3/4 Classical Hodgkin Lymphoma (cHL): 4-Year Update of the Echelon-1 Study

  • Nov 13, 2019
  • Blood
  • Nancy L Bartlett +25
  • Abstract
  • Citations1

Prognostic Impact of a Composite Genetic Profile Defined By Cytogenetics and Next Generation Sequencing at Diagnosis on Treatment Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia

  • Nov 13, 2019
  • Blood
  • Georgina S Daher-Reyes +25
  • Abstract
  • Citations5

Phase II Study of Blinatumomab in Patients with B-Cell Acute Lymphoblastic Leukemia (B-ALL) with Positive Measurable Residual Disease (MRD)

  • Nov 13, 2019
  • Blood
  • Guillaume Richard‐Carpentier +19
  • Abstract

Efficacy of Idelalisib and Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Treated Outside of Clinical Trial. a Report of the Gimema Group

  • Nov 05, 2020
  • Blood
  • Gian Matteo Rigolin +45
  • Abstract

Expression of Major Histocompatibility Complex (MHC) Class II, but Not MHC Class I, Predicts Outcome in Patients with Classical Hodgkin Lymphoma (cHL) Treated with Nivolumab (Programmed Death-1 [PD-1] Blockade)

  • Jun 25, 2021
  • Blood
  • Margaretha G.M Roemer +28
  • Abstract
  • Citations1

Newly Diagnosed AML Patient Samples Demonstrate High Degree of Concordance in Identification of Pathogenic Mutations By Next Generation Sequencing (NGS) Performed at Enrolling Institutions Compared to Central Laboratory Results in the Beat AML Master Trial

  • Nov 13, 2019
  • Blood
  • Uma Borate +27
  • Abstract
  • Citations30

Natural History of Relapsed Myeloma, Refractory to Immunomodulatory Drugs and Proteasome Inhibitors: A Multicenter IMWG Study

  • Dec 02, 2016
  • Blood
  • Shaji Kumar +45
  • Abstract
  • Citations1

HORIZON (OP-106): Melflufen Plus Dexamethasone (dex) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM) - Health-Related Quality of Life (HRQoL) Analysis

  • Nov 05, 2020
  • Blood
  • Albert Oriol +23
  • Abstract
  • Citations11

Subcutaneous Daratumumab with Bortezomib, Cyclophosphamide, and Dexamethasone in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: 18-Month Analysis of the Phase 3 ANDROMEDA Study

  • Nov 05, 2021
  • Blood
  • Raymond Comenzo +29
Cactus Communications logo

Copyright 2026 Cactus Communications. All rights reserved.